再分化使能的 TSHRCART 细胞克服侵袭性甲状腺癌中的抗原丢失
Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers.
这些发现确立了肿瘤再分化作为一种可推广的策略,用于克服抗原丢失并增强CART细胞疗法在甲状腺癌以及可能其他实体瘤中的疗效。
英文原题:The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer.
我们的研究提供了对MTC免疫抑制微环境的见解,并提出CGRP受体作为潜在的治疗靶点。
神经递质是神经免疫回路中的关键调节因子,并与肿瘤进展相关。甲状腺髓样癌(MTC)是一种侵袭性神经内分泌肿瘤,表达神经递质降钙素基因相关肽(CGRP),对化疗和放疗不敏感,免疫疗法的有效性尚不清楚。因此,对肿瘤微环境的全面分析将有助于有效治疗,并为CGRP在神经系统外的功能提供证据。在此,我们比较了MTC和甲状腺乳头状癌(PTC)的单细胞图谱,发现MTC中CGRP的表达与树突状细胞(DC)异常发育相关,其特征为cAMP相关通路的激活和高水平的Kruppel样因子2(KLF2),并与肿瘤浸润T细胞活性受损相关。CGRP受体拮抗剂可以在体外抵消CGRP对DC发育的不利影响。我们的研究提供了对MTC免疫抑制微环境的见解,并提出CGRP受体作为潜在的治疗靶点。
Neurotransmitters are key modulators in neuro-immune circuits and have been linked to tumor progression. Medullary thyroid cancer (MTC), an aggressive neuroendocrine tumor, expresses neurotransmitter calcitonin gene-related peptide (CGRP), is insensitive to chemo- and radiotherapies, and the effectiveness of immunotherapies remains unknown. Thus, a comprehensive analysis of the tumor microenvironment would facilitate effective therapies and provide evidence on CGRP's function outside the nervous system. Here, we compare the single-cell landscape of MTC and papillary thyroid cancer (PTC) and find that expression of CGRP in MTC is associated with dendritic cell (DC) abnormal development characterized by activation of cAMP related pathways and high levels of Kruppel Like Factor 2 (KLF2), correlated with an impaired activity of tumor infiltrating T cells. A CGRP receptor antagonist could offset CGRP detrimental impact on DC development in vitro. Our study provides insights of the MTC immunosuppressive microenvironment, and proposes CGRP receptor as a potential therapeutic target.
MEMBER ACCOUNT
登录成功会直接打开下一页。